Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Circulation · 15.10.2024 · 150 (16) · 1288-1298
DOI: 10.1161/circulationaha.124.067676 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 15.10.2024. Verfasst von Jennifer Linge und 2 weiteren Autor:innen. Beteiligte Einrichtung: AMRA Medical AB, Linköping, Sweden (J.L.). Hauptthemen laut MEDLINE: Weight Loss, Muscle, Skeletal, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 195-mal zitiert (Crossref) und nennt 90 Literaturangaben.
Abstract (Originalsprache)
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, as more weight loss is achieved, there is concern for potential adverse effects on muscle quantity, composition, and function. This primer aims to address whether muscle-related changes associated with weight loss treatments such as GLP-1 RAs may be maladaptive (ie, adversely affecting muscle health or function), adaptive (ie, a physiologic response to weight loss maintaining or minimally affecting muscle health or function), or perhaps an enhanced response to weight loss (ie, improved muscle health or function after treatment). Based on contemporary evidence with the addition of studies using magnetic resonance imaging, skeletal muscle changes with GLP-1 RA treatments appear to be adaptive: changes in muscle volume z-score indicate a change in muscle volume that is commensurate with what is expected given aging, disease status, and weight loss achieved, and the improvement in insulin sensitivity and muscle fat infiltration likely contributes to an adaptive process with improved muscle quality, lowering the probability for loss in strength and function. Nevertheless, factors such as older age and prefrailty may influence the selection of appropriate candidates for these therapies because of risk for sarcopenia. Several pharmacologic treatments to maintain or improve muscle mass designed in combination with GLP-1–based therapies are under development. For future development of GLP-1–based therapies (and other therapies) designed for weight loss, as well as for patient-centered treatment optimization, the introduction of more objective and comprehensive ways of assessing muscle health (including accurate and meaningful assessments of muscle quantity, composition, function, mobility, and strength) is important for the substantial numbers of patients who will likely be taking these medications well into the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AMRA Medical AB, Linköping, Sweden (J.L.).
- Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Sweden (J.L.).
- Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich, Germany (A.L.B.).
- Department of Diabetology, Endocrinology, and Nephrology, University Clinic Tübingen, Eberhard Karls University Tübingen, Germany (A.L.B.).
- German Center for Diabetes Research (DZD), Neuherberg, Germany (A.L.B.).
- Department of Diabetes, Life Sciences & Medicine, Cardiovascular Medicine & Sciences, Kings College London, UK (A.L.B.).
ORCID-Profile: Jennifer Linge, Andreas L Birkenfeld
Zitieren
APA
Linge, J., Birkenfeld, A. L., & Neeland, I. J. (2024). Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?. Circulation, 150(16), 1288-1298. https://doi.org/10.1161/circulationaha.124.067676
Vancouver
Linge J, Birkenfeld AL, Neeland IJ. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?. Circulation. 2024;150(16):1288-1298. doi:10.1161/circulationaha.124.067676
BibTeX
@article{Linge2024,
author = {Linge, Jennifer and Birkenfeld, Andreas L and Neeland, Ian J},
title = {Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?},
journal = {Circulation},
year = {2024},
volume = {150},
number = {16},
pages = {1288--1298},
doi = {10.1161/circulationaha.124.067676}
}
EUVIMED